3rd Workshop on Research & Innovation in Poland:
Research Programme or Linear Accelerator – Radioisotopes and Applications

Production of Radionuclides Using Deuterons or Alpha Particles

Arnaud Guertin et al. on behalf of PRISMA and GIP ARRONAX teams

Subatech

PRISMA
Physics of Radiation InteractionS with Matter and Applications

ARRONAX



22-23 Oct. 2026
Krakow, Poland

3rd Workshop on Research & Innovation in Poland:
Research Programme or Linear Accelerator – Radioisotopes and Applications

Production of Radionuclides Using Deuterons or Alpha Particles for Medical Applications

Arnaud Guertin et al. on behalf of PRISMA and GIP ARRONAX teams

Subatech

PRISMA
Physics of Radiation InteractionS with Matter and Applications

ARRONAX




22-23 Oct. 2026
Krakow, Poland

Personalized nuclear medicine

Imaging and diagnosis


Choose the best treatment


Evaluate its efficacy



Therapy

Destroy tumor cells






The Right Drug To The Right Patient For The Right Disease

At The Right Time With The Right Dosage



Adapted from F. Haddad

Nuclear data: cross section measurements



© European Atomic Energy Community, 2023 - C.L. Fontana (JRC-Geel)

Requirements:

- **Accurate and reliable** data sets
- **Well-defined production pathways** and **decay properties**
- **Optimal production** of specific radionuclides, minimisation/elimination of **impurities, realistic dose** calculations
- Provide **a broad set of nuclear data** in terms of targets, projectiles and energy range in order **to constrain** and **develop** predictive **simulation tools** for nuclear reactions.


Outcomes:

- **Impact on production**
- **Impact on modeling nuclear reactions**

Where medical isotopes are coming from?

Few directly available in nature, belonging to radioactive chain of heavy nuclei

- **Ra-233**: belongs to the radioactive chain of U-235
  Xofigo ($RaCl_2$) available for bone metastases
- **Pb-212/Bi-212**: belongs to thee radioactive chain of ^{232}Th
  2 clinical trials ongoing for NeuroEndocrineTumors (clinical.org)
- **Ac-225** : belongs to the radioactive chain of U-233




BR2 reactor @ SCK•CEN


Most of them are produced artifically

Many of them using neutron induced reactions in **nuclear reactors**

Quick progress and achievements using charged particle induced reactions in **accelerators** like **cyclotrons** and **linacs**



C70XP @ ARRONAX



SPIRAL 2 @ GANIL

Accelerators

Cyclotrons:

- Fixed energy [0 up to ~ 100 MeV]
- Low intensity [0 up to ~ 50 µA]
  - ✓ Cyclone 30XP IBA
    Polatom - CERAD, Poland – FZ Jülich, Germany
  - ✓ Cyclone 70XP IBA
    GIP ARRONAX, France




C70XP @ GIP ARRONAX

Extracted	Energy (MeV)	Max. current (µA)
H^+	30 – 70	2 x 375
D^+	15 – 35	2 x 50
He^{2+}	68	70
HH^+	17	50

LINACS:

- Variable energy [0 up to ~ 20 MeV/A]
- High intensity [0 up to ~ mA*]
  - ✓ ATLAS
    Argonne National Laboratory, USA
  - ✓ SPIRAL 2
    GIE GANIL, France



SPIRAL 2 @ GIE GANIL

Beam	P+	D+	Ions	Ions
A/Q	1	2	< 3	< 6 or 7
Imax (mA)	5	5	1	1
Emin (MeV/A)	2	2	2	2
Emax (MeV/A)	33	20	14.5	8
Max. power (kW)	165	200	44	48

*High LET and “thin targets” [~ tens of µm up to ~ hundreds of µm], **! thermal load**

There is not one fit all accelerator

C-11, N-13,
O-15, F-18,
Cu-64



11 MeV

Ga-67, In-111, I-123,
Tl-201, Ge-68



30 MeV

Sr-82, Sn-117m ...



70 MeV

Linear Accelerator
160 MeV




Sr-82, Sn-117m, Ac-225 ...

PRISMA @ Subatech lab [CNRS, NU, IMT Atlantique]

26 people including students

Isotopes for therapy and diagnosis



Which isotopes for tomorrow's nuclear medicine?

Cross section measurements



Mass separation

Hadronbiology at very high dose rates



Flash radiotherapy

Radiolysis

Nuclear and health

HB

RAMI

PRISMA


Physics of Radiation InteractionS with Matter and Applications

IRMA

SMILES

Detection, ion beam analysis

Detector testing



Archeometry

Materials and environment

Mass separation coupled with laser ionisation

GIP ARRONAX

[Regional Council, CNRS,NU, INSERM, IMT Atlantique, EU]

Accelerator for **R**esearch in **R**adiochemistry and **O**ncology at **N**antes **A**tlanti**X**



3 main fields of investigations:

Radionuclides and **radiopharmaceuticals production** for nuclear medicine


Research in related fields: radiolysis, radiobiology, nuclear physics …

Training of students

The name ARRONAX is a tribute to **Jules Verne, born in Nantes** in 1828.

Aronnax is the name of the main character of the novel «Twenty thousands leagues under the sea » published in 1870

Nautilus




Professor ARONNAX

Jules Verne

ARRONAX Facility


- **Key numbers:**
  - Creation **2008**, commissioned **2010**
  - **70 people** including students
  - **C70XP** and **Kiube 180** coming soon

- **Key features:**
  - Multi-particles
  - High energy
  - High intensity



C70XP cyclotron @ GIP ARRONAX

	Beam	Accelerated ions	Energy (MeV)	Intensity (eµA)	Dual beam
C70XP	Proton	H-	30-70	< 375	Yes
		HH+	17	< 50	No
	Deuton	D-	15-35	< 50	Yes
	Alpha	He++	68	< 70	No
IK18	Proton	H-	18	180	Yes




Cross-section view of the reaction casemates located around the C70XP

- **A range of associated laboratories, 2000 m²:**
  - radiochemistry, biochemistry, radiolabelling,
  - cell culture, chemical analyses,
  - nuclear metrology, quality control, etc.

The radiopharmacy NU hospital / GIP ARRONAX

Purpose: production of radiopharmaceuticals for clinical trials in Europe



GMP S2



In use since May 2018

GMP S3

QI/QO



Final qualification 2023


Several clinical trials performed using **Lu-177** and **Cu-64** (ARRONAX production)

Several clinical trials under preparation using **Lu-177**, **Ac-225**, **At-211** (ARRONAX production) and **Cu-64** (ARRONAX production)



Adapted from F. Haddad

Pipeline ARRONAX



FDA APPROVED

GMP GOOD MANUFACTURING PRACTICE QUALITY PRODUCT


ansm Agence nationale de sécurité du médicament et des produits de santé

New developments on Auger emitters



Adapted from F. Haddad

Wide use of available beams: explore the realm of possibilities



Proton beam

Deuton beam

Alpha beam

And more :

★ Enriched target investigated

Chemical separation studies




Prepared by E. Nigron


Cu-64 to develop theranostic approach


- **Cu-64, main interests:**
  - **Half-life**: **12.7 hours** - not too short, not too long
    - ➢ Suitable for **P**ositron **E**mission **T**omography
  - **Theranostic pair** with Cu-67
    - ➢ **What you see is what you treat**
  - **Applications**
    - ➢ PET imaging of NET - Detectnet (Curium Pharma) - FDA approval date: September 3, 2020


- **Production routes:**
  - **Main:** Ni-64 + p → Cu-64 + n
  - **Alternative:** Ni-64 + d → Cu-64 + 2n

- **Production scheme:**
  - **Enriched Ni-64** electroplated on Au backing
  - Monthly production of $CuCl_2$












Kiube 180 for Cu-64 (F-18)


How to improve Cu-64 availability in France and neighbouring countries (current partners) ?


- Installation of a 18 MeV cyclotron, IK18, IBA Kiube 180, with a solid target system customized connected to the existing one for C70XP
- **Still leave room for research with deuteron beam**











Lu-177

Objectives: explore alternative production route of Lu-177 from Yb-nat - $T_{1/2}$ = 6.7 d
Suitable for **β- targeted therapy**

Outcomes:
- Extend the cross section at higher energy
- Measure the ratio Lu-177m/Lu-177g




Figure 3: Excitation function of ^{176}Yb(d,x)^{177cum}Lu nuclear reaction compared to other published data and TENDL (2023).

ELSEVIER
Applied Radiation and Isotopes
Volume 227, January 2026, 112263

Deuteron-induced nuclear reactions to produce ^{177}Lu: Extension of cross-sections data up to 33 MeV and impact on purity

E. López-Melero [a], E. Nigron [b], F. Haddad [b c], J. Praena [a]




Figure 2: HPGe spectrum acquired six months after EOB with a counting time of 13 days. The marked regions indicate the most relevant γ-lines associated with the decay of ^{177m}Lu

- Define the lowest detection limit for Lu-177m measurement ($T_{1/2}$ = 160.44 d)



E. Lopez

Alpha beam interests

Some interesting considerations for production of medical isotopes

- Access to a **higher cross section**: 700 mb Ca-40[96.941%](α,x)**Sc-43** – 350 mb Ca-43[0.135%](p,n)**Sc-43**
- Reuse **existing process** in targetry, chemistry: **Cu-64** target, chemistry and recycling of Ni-64 for **Cu-67** prod.
- Facilitate **target manufacturing**, irradiation and enhanced specific activity: use of Cd/Cd-116 for **Sn-117m** prod.
- Use a **monoisotopic target**: Cs-133 [alkaline !] for **La-135** instead of Ba-nat [low thermal conductivity]
  Non-standard positron emitters, Auger-based targeted internal radiotherapy …
- Avoid **radioactive target material**: Tc target for **Ru-97**, Po target for **At-211**



Spallation reaction
- lower yield
- higher level of impurity

Bi-209(α,2n)At-211
- monoisotopic target
- high radionuclidic purity
- GBq quantities


At-211 to eradicate tumors using TAT

A limited number of alpha emitter candidates

Radionucliide	Half life	# α / decay	Eγ (keV)
Tb-149	4,1 h	0,17 (β et ε)	165
At-211	**7,2 h**	**1**	79
Bi-212	1 h	1 (β)	727
Bi-213	45 m	1 (2β)	440
Ra-223	11,4 d	4 (2β)	269
Ac-225	10 d	4 (2β)	100
Th-226	31 m	4	111
Th-227	18,7 d	5 (2β)	256


Highly cytotoxic, Eα [5-9] MeV
potentially more than β radiation

Better preservation of healthy tissue,
range of 40 to 100 µm in water,
a few cell's length



Supiot S. et al. Cancer 2002. 94: 1202-9


High Relative Biological Efficacy
High LET, ~ 80 keV/µm




The essential Physics of Medical Imaging, Book, Bushberg et al., 2002

At-211 interests and production

- **At-211, main interests:**
  - **Half-life**: **7.2 hours** - not too short, not too long
    - Suitable for **R**adio**P**harmaceutical **T**herapy
  - **One alpha particle** per decay
    - Better **control of the deposited dose**
  - **Accelerator** production
    - IBA : C30XP, multi-particules
    - ACSI : TR-ALPHA, 30 MeV "only alpha"
- **Production route:** **Bi-209 + α → At-211 + 2n**
- **Keep in mind:**
  - **Precise beam energy** adjustment
    - **Avoiding the production of At-210 - (α,3n) reaction**
  - The At-210 begins to be produced above 28.613 MeV
    - Half-life 8.1 hours
    - 99.8% CE towards **Po-210** with a half-life of 138.4 days
- **Production scheme:** **energy degrader**, home made target, dry extraction






At-211 production: C70XP ARRONAX


Production route: $^{209}Bi + \alpha \rightarrow {}^{211}At + 2n$

Production scheme:

- 68 MeV alpha particle beam
- **Energy degrader in Al or graphite to reach 28 MeV**
- Target material evaporated under vacuum
- Irradiated in an IBA rabbit system
- At-211 extraction using dry chemistry
- At-211 recovered in chloroform




The IBA rabbit system (left) and
a target for astatine production (right)



In vivo application:

- At-211-labelled anti-mCD138 in mouse syngeneic multiple myeloma



Production capacity:

- 3-4 batches/month
- Between 0.9 and 1.2 GBq EOB

Gouard S et al. Cancers (Basel). 2020 Sep 22;12(9):2721

Optimizing ^{211}At production SPIRAL 2

- **Alpha beams available at GIE GANIL**
  - SPIRAL2 : He2+ 80 MeV to 8 MeV
  - ^{209}Bi irradiation possible


    Bi-209(α,3n)At-210 until 35 MeV
  - Experiment carried out in late September 2022

    Energies around the threshold
  - Measurement techniques for the isotopes of interest


    Gamma spectroscopy

- **Analysis of the experience and publication**
  - S. Ansari-Chauveau, A-M. Frelin Labalme
  - Publication in Physics in Medicine and Biology in 2025






SPIRAL2 building and data acquisition room dedicated to experiments – September 2022



Device for the 'on-line' measurement of gamma radiation




'Offline' gamma radiation measurement device

Applied Radiation and Isotopes 225 (2025) 112061

Contents lists available at ScienceDirect

Applied Radiation and Isotopes

journal homepage: www.elsevier.com/locate/apradiso



Optimizing ^{211}At production cross section by studying the rise of ^{210}At cross section: First measurement using Linac SPIRAL2

S. Ansari-Chauveau [a,*], A-M. Frelin [a], G. de France [a], A. Guertin [b], F. Haddad [b,c], X. Ledoux [a], J. Mrázek [d], E. Šimečková [d]

[a] GANIL, Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DSM-CNRS/IN2P3, Boulevard H. Becquerel, Caen 14076, France
[b] SUBATECH, Nantes Université, IMT Atlantique, CNRS/IN2P3, 3 Rue Alfred Kastler, Nantes 44300, France
[c] GIP ARRONAX, 1 rue Aronnax, Saint-Herblain 44817, France
[d] Nuclear Physics Institute CAS, Řež 25068, Czech Republic



A.M. Frelin



S. Ansari-Chaveau


At-210 production near the threshold

- **Alpha beams available at GIE GANIL**
  - Measurement of the reaction threshold
  - In particular, with regard to contaminants
    - ➢ **Improved purity**

- **High-efficiency γ-spectrometry device**
  - Accuracy
  - Statistics
    - ➢ **Lower production cross-section values**

- **Analysis of the experience and publication**
  - Confirmation of Lambrecht's work
  - **Target thickness** affects the energy error

- **Perspectives**
  - Measurements of cross-sections for the **monitor reactions**
  - Exploring the **different mass regions**
  - Setting up **a current measurement device**




Internal Target for At-211


How to improve the availability of At-211@ ARRONAX?


Upgrade of the machine: development of an internal target to intercept the beam at the right energy (28-29 MeV)

- No more need to degrade the beam energy and better control of At-210 production
- **Limitation will be now the target itself**



Commissionning under way






Target handling after irradiation


Our goals: improve both the quality and the quantities of the final product – participation to Accelerate.EU

Er-165 to develop Auger therapy

- $T_{1/2}$ = 10.36 h
- Er-165 decays at 100% to Ho-165 (stable)
- **Pur Auger electron** (AE) and X emitter. 7 AEs/decay
- **No gamma emissions.**



0.5 AE at 20 eV
4 AE at 100 eV
1.5 AE at 1 keV
0.5 AE at 5 keV



Ku et al. EJNMMI Radiopharmacy and Chemistry, 2019

→ Ideal for **Auger electron dosimetry studies**.




Prepared by E. Nigron

Er-165 production route

It can be produced directly → but the decay time must be managed.

Route identified




- Tm-165 (30h)/ Er-165 (10h)
- Ho mono-isotopic target
- Close Tm contaminants decay into stable nuclei
  - ➢ High **Radionuclidic purity**
- Requests a high-energy alpha beam (~60 MeV)





Prepared by E. Nigron

Tm-165/Er-165 generator

Objective: production of Er-165,a pure AE-emitting radionuclide chemically matched to clinical therapeutic radionuclide Lu-177, from a generator using functionalized porous materials as a support









E. Nigron and A.C. Bonraisin




Outcomes: setup of Tm-165 production of 100 MBq for research in radiochemistry and Er-165 radiolabeling. The establishment of **thick-target production** has **confirmed production yields**.

Tm-165 Thick Target Yield

- A range around 50 MeV **optimize the production of Tm-165**.
- Another range around 56 MeV **limit the production of Tm-166.**

Post-production scenario defined with a chemical separation EOB +2h.

180% of Tm-165 activity is recovered as Er-165 after 3 days with an 8-hour elution cycle.





What are **the purity and molar activity**? How does it compare to the direct route?

Comparison of production routes

Calculations for a 50 µm target at 100% Ho-165 at 7 µA for 2 h (production characteristics used at GIP ARRONAX).

Route	Energy range (MeV)	Activity (MBq)		Molar activity (GBq/nmol)
Ho-165(p,n)Er-165	9.9 – 9	146		1.8
Ho-165(d,2n)Er-165	13.2 – 12.0	524		2.9
Ho-165(α,4n)Tm-165	49.8 – 46.7	204 of Tm-165	367 of Er-165	1.9* – 3.9
	57.8 – 55.0	101 of Tm-165	182 of Er-165	2.5* – 3.9

Target purity not taken into account

*for 1st elution

- The deuton pathway has the **highest production yield**.
- The alpha route has **the highest molar activity**.
- And with the alpha route, Er is **available over a longer period of time**.



Prepared by E. Nigron


A dynamic collaborative network





E. Nigron


Publications since 2025 :


INFN Milano
INFN Legnaro
CEA
IFMIF-Dones
CEMHTI (soon)
IJClab
New collaborations under discussion














PRISMAP+ Consortium



Data collected: proton beam

Ac-225 from Th-232(p,x)	C. Duchemin et al, Phys Med Biol **60** (2015) **931-946**
Ra-223 from Th-232(p,x)	C. Duchemin et al, Phys Med Biol **60** (2015) **931-946**
Fission fragment distribution from Th-232(p,x)	V. Métivier et al, EPJ Web of Conf. **146** (2017) **08008**
Dy-155/Tb-155 from Tb-159	R. Formento Cavaier, Radiat Phys and Chem 224 (2024) 112069
Dy-157,159, Gd-151,153, Tb-153,154m1,154m2,156	
Tb-155 new data set for $^{h.e.155}$Gd(p,x)	M. Bouteculet et al, Appl Radiat Isot **213** (2024) **111485**
	M. Bouteculet et al, Appl Radiat Isot **229** (2026) **112375**
Tb-149 from Gd-nat(p,x)	R. Formento Cavaier, PhD thesis (2019)
Tb-150,151,152,153,154,154m2,155,156	Nucl Instr Meth Phys Rev B **478** (2020) **174-181**
Cu-67 from Zn-68(p,2p)	G. Pupillo et al., Nucl Instr Meth Phys Res B **415** (2018) **41-47**
Ga-67 from (p,2n), Ga-66 from (p,3n)	
Cu-67 and Cu-64 from Zn-70(p,x)	G. Pupillo et al., Radiochimica Acta **108** (2020) **593-602**
Ga-67, Ga-66, Zn-65 and Zn-69m	
Sc-47,Sc-44m,Sc-44 from V-nat(p,x)	G. Pupillo et al., Il Nuovo Cimnto **42 C** (2019) **139**
Sc-48,46,43, K-43,42 ,V-48, Cr-51,49,48	G. Pupillo et al., J Radioanal Nucl Chem **322** (2019) **1711**
Sc-47,Sc-44m,Sc-44 from Ti-48(p,x)	F. Barbaro et al., Phys. Rev. C **104** (2021) **044619**
Sc-47,Sc-46, Sc-44m, Sc-44g, Sc-43, V-48	L. Mou et al., Pharmaceuticals **17** (2024) **26**
Sc-47 first set of data from Ti-49(p,x)	
Sc-43,44m,44g,46g,46m,48, V-48, K-43	L. de Dominis et al., Appl Radiat Isot **226** (2025) **112106**
Sc-47 from enriched Ti-48,49,50	L. de Dominis et al., ND2025 oral presentation (2025)
Sc-43 from V(p,x)	G. Pupillo et al., Nucl Instr Meth Phys Res B **464** (2020) **32-35**
Monitor reactions on Ti, Ni and Cu	E. Garrido et al., Nucl Instr Meth Phys Res B **383** (2016) **191-212**

Data collected: deuteron beam

Pa-230 for U-230/Th-226 New data set for Th-232(d,x)	C. Duchemin et al., Nucl Med Biol **41** (2013) **19-22**
Fission fragment distribution from Th-232(d,x)	V. Métivier et al, EPJ Web of Conf. **146** (2017) **08008**
Pb-203 from Tl-205(d,4n)	T. Sounalet et al., Appl Radiat Iso **205** (2024) **111190**
Hg-197m New data set for Au-197(d,x)	E. Nigron, PhD thesis 2019, to be published
Re-186g New data set for W-186(d,x)	C. Duchemin et al, Appl Radiat Isot **97** (2015) **52-58**
Lu-177cum,g+m from Yb-nat(d,x)	M. E. Lopez Melero, Appl Radiat Isot **227** (2026) **112263**
Lu-176cum,175cum,174g+m,m,g,173,172g+m,171g+m,170g+m,169cum,g+m,Tm-167,168	
Tb-161 from Gd-160(d,n)	E. Nigron et al., Appl Radiat Iso **200** (2023) **110927**
Tb-155 New data set for Gd-nat(d,x)	C. Duchemin et al, Appl Radiat Isot **118** (2016) **281-289**
Tb-155,156,160,161 from Dy-nat(d,x)	M. Colucci et al., Eur Phys Jour Plus **137** (2022) **1180**
Tb-155 from Gd-155(d,2n)	Y. Wang et al. Appl Radiat Isot **201** (2023) **110996** V. Rhoden et al. **WTTC19** (2024)
Rh-105 New data set for Ru-104(d,x)	M. Sitarz, PhD thesis 2019
Cu-67 New data set for Zn-70(d,x)	E. Nigron, PhD thesis 2019 and Front. Med. **8** (2021) **674617**
Cu-61 from Ni-nat(d,x)	L. Puren et al., Proceedings ND2025 (2025) **in review**
Mn-52g from Cr-nat(d,x)	F. Bianchi et al., Appl Radiat Isot **166** (2020) **109329**
Sc-44 New data set for Ca-44(d,x)	C. Duchemin et al, Phys Med Biol **60** (2015) **6847-6864**
Monitor reactions on Ti, Ni	C. Duchemin et al, Appl Radiat Isot **103** (2015)**160-165**

Data collected: alpha beam


Tm-165/Er-165 from Ho-165 Tm-166,167	E. Nigron et al. , CYCLEUR oral pres. (2025) article **in preparation**
Tb-155 from Eu-nat(α,x) Tb-156,154,153,152,151,150,149	M. Colucci et al., Journal of Physics G **52** (2025) **115102**
Sn-117m New data set from Cd-116(α,x) Sn-110,113, In-109,110g,111,114m1+m2 Cd-115g	C. Duchemin et al, Appl. Radiat. Isot. **115** (2016) **113-124**
Ag-111 from Pd-nat(α,x) Ag-105,106,110m	L. Puren et al., Proceedings ND2025 **in review**
Mo-99 New data set from Zr-96(α,n)	G. Pupillo et al., J. Radioanal. Nucl. Chem. **302** (2014), 2, **911-917**
Ru-97 New data set from Mo-nat(α,x) Zr-89, Tc-95g,96, Mo-99	M. Sitarz et al, Instruments **3** (2019) **7**
Cu-61 from Co-59(α,2n) Cu-60, Co-61	M. Colucci et al., Appl. Radiat. Isot. **229** (2026) **112377**

Monitor reactions on Cu, Ti, Ni

Fundamental and applied research

Activation of materials for both applied and basic research, especially with alpha particles

- ✓ **Nuclear data**: cross section measurements, comparison with nuclear model calculations
  - Reaction mechanism, excitation function, isomeric cross section
- ✓ **Radioisotope production**
  - Optimum production, minimization of impurities
  - Realistic dose calculation
- ✓ **Nuclear structure data:** high-spin level
- ✓ **Astrophysics:** r process



Adapted from S. Benck, PhD thesis, 1999

⇨ Influence on the calculated production cross section values

Activities framework: translational research

GIP ARRONAX possesses 2 cyclotrons:

- a versatile C70XP cyclotron allowing a wide range of radionuclide production as well as irradiation research.
- a Kiube-180 cyclotron, IK18, under final commissioning

GIP ARRONAX and PRISMA are developing and producing radionuclides but also radiopharmaceuticals for research in nuclear medicine

PRISMA is also working on:

- Which isotopes for tomorrow's nuclear medicine?
  - Systematic cross section measurements => impact on modeling
- Hadronbiology at very high dose rates
- Detection, ion beam analysis
- Mass separation coupled with laser ionisation



These work can only be achieved through **collective work**
at all scales (local, national and international) and with all partners (academia and industry)

Thank you for your attention

The **ARRONAX** project is supported by:
Regional Council of Pays de la Loire
Nantes Université
French government (CNRS, INSERM)
European Union.

Subatech laboratory is supported by:
CNRS Nucléaire et Particules
Nantes Université
IMT Atlantique

This work has been, in part, supported by a grant from the French National Agency for Research called "Investissements d'Avenir", Equipex Arronax-Plus noANR-11-EQPX-0004, Labex IRON no ANR-11-LABX-18-01, ISITE NExT no ANR-16-IDEX-007, EU Horizon 2020 PRISMAP program n° 101008571, Accelerate.EU program n° 101173001.

αccelerate.EU


How to improve the availability of At-211@ the european level?

αccelerate.EU – A €16 Mn initiative to reach a resilient and strategic EU autonomy for a greater patient access to **alpha therapies**

αccelerate.EU

Clinical trials for unmet clinical needs

Innovative **co-clinical** approach to boost alpha theranostic uptake



Dedicated **alpha-cyclotron** to enable ^{211}At production network

Production of ^{211}At every week over 5 years

Work packages

- Early supply
- Ligand & radiolabeling
- Preclinical & co-clinical
- Clinical trials
- Production scale-up

Guertin Arnaud - Arnaud.Guertin@subatech.in2p3.fr

innovative health initiative

European Commission